There are 2789 resources available
523P - AFP-maytansine conjugate: A novel targeted cancer immunotherapy
Presenter: Igor Sherman
Session: ePoster Display
621P - Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): Clinical subgroup analysis from the phase III HERO study
Presenter: Bertrand Tombal
Session: ePoster Display
622P - Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)
Presenter: Bertrand Tombal
Session: ePoster Display
558TiP - Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies
Presenter: Vincent Ribrag
Session: ePoster Display
625P - TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer
Presenter: Caterina Aversa
Session: ePoster Display
626P - Estimation of overall survival with subsequent treatment effect by applying inverse probability of censoring weighting in the LATITUDE study
Presenter: Nobuaki Matsubara
Session: ePoster Display
627P - Phase II neoadjuvant trial of the anti–B7-H3 antibody, enoblituzumab, in men with localized prostate cancer: Safety, efficacy and immune correlates
Presenter: Eugene Shenderov
Session: ePoster Display
628P - Universal germline testing of prostate cancer patients: Are genetic testing guidelines an aid or an impediment to precision therapy?
Presenter: Neal Shore
Session: ePoster Display
629P - Patient-reported outcomes in prostate cancer patients receiving PSMA-targeted radionuclide therapy
Presenter: Brian Gonzalez
Session: ePoster Display
630P - Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial
Presenter: Christian Gratzke
Session: ePoster Display